Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?
Clinical Science · 05.06.2024 · 138 (11) · 687-697
DOI: 10.1042/cs20240605 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Science, online erschienen am 05.06.2024. Verfasst von Phil Ambery und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Endothelin-1, Endothelium, Vascular. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca (AstraZeneca PLC).
Abstract (Originalsprache)
Endothelin A and B receptors, together with sodium-glucose cotransporter-2 (SGLT-2) channels are important targets in improving endothelial function and intervention with inhibitors has been the subject of multiple mechanistic and clinical outcome trials over recent years. Notable successes include the treatment of pulmonary hypertension with endothelin receptor antagonists, and the treatment of heart failure and chronic kidney disease with SGLT-2 inhibitors. With distinct and complementary mechanisms, in this review, we explore the logic of combination therapy for a number of diseases which have endothelial dysfunction at their heart.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Information Practice Late Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
- Department of Clinical Pharmacology and Therapeutics, Cambridge University Hospitals NHS Foundation Trust, Cambridge, CB20QQ, U.K.
- Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Addenbrooke's Hospital, Cambridge, U.K.
ORCID-Profile: Phil Ambery, Anthony P Davenport
Förderung
- AstraZeneca (AstraZeneca PLC)
Zitieren
APA
Ambery, P., Greasley, P. J., Menzies, R. I., Brynne, L., Kulkarni, S., Oscarsson, J., & Davenport, A. P. (2024). Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?. Clinical Science, 138(11), 687-697. https://doi.org/10.1042/cs20240605
Vancouver
Ambery P, Greasley PJ, Menzies RI, Brynne L, Kulkarni S, Oscarsson J, et al. Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?. Clinical Science. 2024;138(11):687-697. doi:10.1042/cs20240605
BibTeX
@article{Ambery2024,
author = {Ambery, Phil and Greasley, Peter J and Menzies, Robert I and Brynne, Lena and Kulkarni, Spoorthy and Oscarsson, Jan and Davenport, Anthony P},
title = {Targeting the endothelium by combining endothelin-1 antagonism and SGLT-2 inhibition: better together?},
journal = {Clinical Science},
year = {2024},
volume = {138},
number = {11},
pages = {687--697},
doi = {10.1042/cs20240605}
}
EUVIMED